Upcoming event

From October 15 to October 19, Radboud translational medicine will attend the 29th annual congress of the European Association of Nuclear Medicine.
Visit us at booth #59!

Other news

First Patient Dosed with TLX250-CDx in Italy for ccRCC

The below product is manufactured at RTM First Patient dosed with TLX250-CDx in Italy for ccRCC Th...

LinkedIn post ESRR2024

📢 Important update on EU #GMP Annex 1 at #ESRR2024!  The revised EU GMP Annex 1, effecti...

18F-FDOPA now available

Fluorodopa (18F) is now available for clinical studies and - with doctor's certificate - for routine...

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...

News